StemCells announce first transplant in phase 1,2 trial in AMD StemCells announced dosing of the first high-dose patient in the company's Phase 1,2 clinical trial in dry age-related macular degeneration.The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with 1M HuCNS-SC cells. The first four patients each received a dose of 200K cells. An independent Data Safety Monitoring Committee conducted a review of the trial data to date, and found no safety issues to preclude the trial from proceeding to the high dose.
StemCells transplants first patient in clinical trial for macular degeneration StemCells announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of geographic atrophy, the most advanced form of dry age-related macular degeneration